Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
News|Articles|December 21, 2016
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-01-04-2017
- Volume 12
- Issue 1
Aurinia and Lonza Enter into Manufacturing Agreement
Author(s)Pharmaceutical Technology Editors
The companies entered into a manufacturing agreement for voclosporin active pharmaceutical ingredient.
Advertisement
Aurinia Pharmaceuticals announced on Dec. 19, 2016 that the company has entered into a long-term agreement with Lonza for the manufacture of voclosporin API. This agreement follows a multi-year clinical manufacturing relationship where the companies have refined the process and analytical methods to produce clinical and commercial supplies of voclosporin. Under the terms of the agreement, Lonza will produce cGMP-grade voclosporin drug substance for use in Aurinia’s Phase III lupus nephritis (LN) clinical program and for future commercial use. The agreement also provides an option for Lonza to exclusively supply API for up to 20 years.
Source:
Articles in this issue
over 9 years ago
New Catalysts Enable Cross-Coupling Reactionsover 9 years ago
Outsourced Testing and Manufacturing Support Biosmiliar Projectsalmost 10 years ago
AGC Asahi Glass Acquires CMC Biologicsalmost 10 years ago
Three Novasep Facilities Pass FDA Inspectionalmost 10 years ago
Vetter Begins Manufacturing on Clinical Syringe Filling Linealmost 10 years ago
Fluor Builds Diabetes API Manufacturing Facility for Novo Nordiskalmost 10 years ago
Lonza to Acquire Capsugelalmost 10 years ago
DuPont Receives Grant from Bill & Melinda Gates FoundationAdvertisement
Related to this article
This article discusses risk-based lifecycle governance, system implementation considerations, and the progression of batch record control from paper-based to fully electronic systems.
Ronald Piervincenzi, USP, explains why manufacturers should act now and how benchmarking could reward reliable generic drug suppliers.
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
Florin Muraru, Gourav Pandey, and Richard Jaenisch explain where human sign-off belongs as multi-agent AI and document-parsing models reach GxP.
In this episode of Ask the Expert, Siegfried Schmitt, PhD, vice president, Technical at Parexel, and Susan J. Schniepp, distinguished fellow at Nelson Labs, discuss how companies should approach post-approval changes to their CMC regulatory filings.
The EC has approved AstraZeneca's Trixeo Aerosphere as the first single-inhaler triple-combination therapy for asthma in the EU, based on phase e data showing improved lung function and fewer severe exacerbations in patients uncontrolled on standard ICS/LABA treatment.
In this episode of Pharma Fundamentals, Dr. Aleksandra Zuraw, senior veterinary pathologist at Charles River, provides an introduction to the use of digital pathology in drug development.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pharma Fundamentals: Digital Pathology in Drug Development, Part 1
2
PharmTech’s Weekly Roundup—September 25, 2026
3
Ask the Expert: Post-Approval Changes
4
Weekly Basal Insulin Efsitora: A New Biologics CMC Benchmark
5